Table of Contents Author Guidelines Submit a Manuscript
Anemia
Volume 2012 (2012), Article ID 563251, 20 pages
http://dx.doi.org/10.1155/2012/563251
Review Article

Management of Anemia of Inflammation in the Elderly

1Department of Obstetrics and Gynecology, Sirai Hospital, 09013 Carbonia, Italy
2Department of Medical Oncology, University of Cagliari, 09124 Cagliari, Italy

Received 8 April 2012; Revised 22 July 2012; Accepted 7 August 2012

Academic Editor: Eitan Fibach

Copyright © 2012 Antonio Macciò and Clelia Madeddu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Guralnik, R. S. Eisenstaedt, L. Ferrucci, H. G. Klein, and R. C. Woodman, “Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia,” Blood, vol. 104, no. 8, pp. 2263–2268, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. S. D. Denny, M. N. Kuchibhatla, and H. J. Cohen, “Impact of anemia on mortality, cognition, and function in community-dwelling elderly,” The American Journal of Medicine, vol. 119, no. 4, pp. 327–334, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. G. J. Izaks, R. G. J. Westendorp, and D. L. Knook, “The definition of anemia in older persons,” The Journal of the American Medical Association, vol. 281, no. 18, pp. 1714–1717, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. K. V. Patel, T. B. Harris, M. Faulhaber et al., “Racial variation in the relationship of anemia with mortality and mobility disability among older adults,” Blood, vol. 109, no. 11, pp. 4663–4670, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. B. W. J. H. Penninx, M. Pahor, R. C. Woodman, and J. M. Guralnik, “Anemia in old age is associated with increased mortality and hospitalization,” The Journals of Gerontology A, vol. 61, no. 5, pp. 474–479, 2006. View at Google Scholar · View at Scopus
  6. N. A. Zakai, R. Katz, C. Hirsch et al., “A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the cardiovascular health study,” Archives of Internal Medicine, vol. 165, no. 19, pp. 2214–2220, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Peters, L. Burch, J. Warner, N. Beckett, R. Poulter, and C. Bulpitt, “Haemoglobin, anaemia, dementia and cognitive decline in the elderly, a systematic review,” BMC Geriatrics, vol. 8, article 18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. P. H. M. Chaves, B. Ashar, J. M. Guralnik, and L. P. Fried, “Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women. Should the criteria currently used to define anemia in older people be reevaluated?” Journal of the American Geriatrics Society, vol. 50, no. 7, pp. 1257–1264, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. B. W. J. H. Penninx, J. M. Guralnik, G. Onder, L. Ferrucci, R. B. Wallace, and M. Pahor, “Anemia and decline in physical performance among older persons,” The American Journal of Medicine, vol. 115, no. 2, pp. 104–110, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. A. R. Atti, K. Palmer, S. Volpato, G. Zuliani, B. Winblad, and L. Fratiglioni, “Anaemia increases the risk of dementia in cognitively intact elderly,” Neurobiology of Aging, vol. 27, no. 2, pp. 278–284, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. H. H. Atkinson, M. Cesari, S. B. Kritchevsky et al., “Predictors of combined cognitive and physical decline,” Journal of the American Geriatrics Society, vol. 53, no. 7, pp. 1197–1202, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Riva, M. Tettamanti, P. Mosconi et al., “Association of mild anemia with hospitalization and mortality in the elderly: the Health and Anemia population-based study,” Haematologica, vol. 94, no. 1, pp. 22–28, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Ferrucci and L. Balducci, “Anemia of aging: the role of chronic inflammation and cancer,” Seminars in Hematology, vol. 45, no. 4, pp. 242–249, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. W. B. Ershler, K. Chen, E. B. Reyes, and R. Dubois, “Economic burden of patients with anemia in selected diseases,” Value in Health, vol. 8, no. 6, pp. 629–638, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Woodman, L. Ferrucci, and J. Guralnik, “Anemia in older adults,” Current Opinion in Hematology, vol. 12, no. 2, pp. 123–128, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. National Health Nutrition Examination Survey, Anthropometric Reference Data, United States. 1988–1994, http://www.cdc.gov/nchs/about/major/nhanes/.
  17. W. W. Pang and S. L. Schrier, “Anemia in the elderly,” Current Opinion in Hematology, vol. 19, no. 3, pp. 133–140, 2012. View at Google Scholar
  18. E. Çoban, A. Timuraǧaoǧlu, and M. Meriç, “Iron deficiency anemia in the elderly: prevalence and endoscopic evaluation of the gastrointestinal tract in outpatients,” Acta Haematologica, vol. 110, no. 1, pp. 25–28, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Andrès, H. Fothergill, and M. Mecili, “Efficacy of oral cobalamin (vitamin B12) therapy,” Expert Opinion on Pharmacotherapy, vol. 11, no. 2, pp. 249–256, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Andrès, L. Federici, K. Serraj, and G. Kaltenbach, “Update of nutrient-deficiency anemia in elderly patients,” European Journal of Internal Medicine, vol. 19, no. 7, pp. 488–493, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. C. N. Roy, “Anemia of inflammation,” Hematology, vol. 2010, pp. 276–280, 2010. View at Google Scholar · View at Scopus
  22. E. R. Stadtman, “Protein oxidation in aging and age-related diseases,” Annals of the New York Academy of Sciences, vol. 928, pp. 22–38, 2001. View at Google Scholar · View at Scopus
  23. A. Azzi, K. J. A. Davies, and F. Kelly, “Free radical biology—terminology and critical thinking,” FEBS Letters, vol. 558, no. 1–3, pp. 3–6, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Galaris, M. Mantzaris, and C. Amorgianiotis, “Oxidative stress and aging: the potential role of iron,” Hormones, vol. 7, no. 2, pp. 114–122, 2008. View at Google Scholar · View at Scopus
  25. W. Dröge and H. M. Schipper, “Oxidative stress and aberrant signaling in aging and cognitive decline,” Aging Cell, vol. 6, no. 3, pp. 361–370, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. “Starting 2012: Sod2, DGAT1, p53, SPARC, QTL and reprogramming in aging,” Aging, vol. 4, no. 3, pp. 1–10, 2012.
  27. J. Tschopp, “Mitochondria: sovereign of inflammation?” European Journal of Immunology, vol. 41, no. 5, pp. 1196–1202, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Zhou, A. S. Yazdi, P. Menu, and J. Tschopp, “A role for mitochondria in NLRP3 inflammasome activation,” Nature, vol. 469, no. 7329, pp. 221–226, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. O. Gross, C. J. Thomas, G. Guarda, and J. Tschopp, “The inflammasome: an integrated view,” Immunological Reviews, vol. 243, no. 1, pp. 136–151, 2011. View at Google Scholar
  30. J. C. Leemans, S. L. Cassel, and F. S. Sutterwala, “Sensing damage by the NLRP3 inflammasome,” Immunological Reviews, vol. 243, no. 1, pp. 152–162, 2011. View at Google Scholar
  31. F. Bauernfeind, A. Ablasser, E. Bartok et al., “Inflammasomes: current understanding and open questions,” Cellular and Molecular Life Sciences, vol. 68, no. 5, pp. 765–783, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. S. M. Ye and R. W. Johnson, “Regulation of interleukin-6 gene expression in brain of aged mice by nuclear factor κB,” Journal of Neuroimmunology, vol. 117, no. 1-2, pp. 87–96, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Franceschi, M. Bonafè, S. Valensin et al., “Inflamm-aging. An evolutionary perspective on immunosenescence,” Annals of the New York Academy of Sciences, vol. 908, pp. 244–254, 2000. View at Google Scholar · View at Scopus
  34. J. P. de Magalhães, J. Curado, and G. M. Church, “Meta-analysis of age-related gene expression profiles identifies common signatures of aging,” Bioinformatics, vol. 25, no. 7, pp. 875–881, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Singh and A. B. Newman, “Inflammatory markers in population studies of aging,” Ageing Research Reviews, vol. 10, no. 3, pp. 319–329, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Salminen, J. Huuskonen, J. Ojala, A. Kauppinen, K. Kaarniranta, and T. Suuronen, “Activation of innate immunity system during aging: NF-κB signaling is the molecular culprit of inflamm-aging,” Ageing Research Reviews, vol. 7, no. 2, pp. 83–105, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Schroder, R. Zhou, and J. Tschopp, “The NLRP3 inflammasome: a sensor for metabolic danger?” Science, vol. 327, no. 5963, pp. 296–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Zhou, A. Tardivel, B. Thorens, I. Choi, and J. Tschopp, “Thioredoxin-interacting protein links oxidative stress to inflammasome activation,” Nature Immunology, vol. 11, no. 2, pp. 136–140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. M. J. Morgan and Z. G. Liu, “Crosstalk of reactive oxygen species and NF-κB signaling,” Cell Research, vol. 21, no. 1, pp. 103–115, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Salminen, K. Kaarniranta, and A. Kauppinen, “Inflammaging: disturbed interplay between autophagy and inflammasomes,” Aging, vol. 4, no. 3, pp. 1–10, 2012. View at Google Scholar
  41. C. Gemma, “Neuroimmunomodulation and aging,” Aging and Disease, vol. 1, no. 3, pp. 169–172, 2010. View at Google Scholar
  42. W. B. Ershler and E. T. Keller, “Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty,” Annual Review of Medicine, vol. 51, pp. 245–270, 2000. View at Publisher · View at Google Scholar · View at Scopus
  43. E. J. Goetzl, M. C. Huang, J. Kon et al., “Gender specificity of altered human immune cytokine profiles in aging,” The FASEB Journal, vol. 24, no. 9, pp. 3580–3589, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Ferrucci, R. D. Semba, J. M. Guralnik et al., “Proinflammatory state, hepcidin, and anemia in older persons,” Blood, vol. 115, no. 18, pp. 3810–3816, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. G. J. Vanasse and N. Berliner, “Anemia in elderly patients: an emerging problem for the 21st century,” Hematology, vol. 2010, pp. 271–275, 2010. View at Google Scholar · View at Scopus
  46. L. Ferrucci, J. M. Guralnik, S. Bandinelli et al., “Unexplained anaemia in older persons is characterised by low erythropoietin and low levels of pro-inflammatory markers,” British Journal of Haematology, vol. 136, no. 6, pp. 849–855, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. N. G. Testa, “Structure and regulation of the erythroid system at the level of progenitor cells,” Critical Reviews in Oncology/Hematology, vol. 9, no. 1, pp. 17–35, 1989. View at Google Scholar · View at Scopus
  48. B. L. Ebert and H. F. Bunn, “Regulation of the erythropoietin gene,” Blood, vol. 94, no. 6, pp. 1864–1877, 1999. View at Google Scholar · View at Scopus
  49. J. B. Sherwood, “The chemistry and physiology of erythropoietin,” Vitamins and Hormones, vol. 41, pp. 161–211, 1984. View at Google Scholar · View at Scopus
  50. G. L. Semenza, “Hypoxia-inducible factor 1 (HIF-1) pathway,” Science's STKE, vol. 2007, no. 407, p. cm8, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. E. Goldwasser and J. B. Sherwood, “Radioimmunoassay of erythropoietin,” British Journal of Haematology, vol. 48, no. 3, pp. 359–363, 1981. View at Google Scholar · View at Scopus
  52. E. A. Price, “Aging and erythropoiesis: current state of knowledge,” Blood Cells, Molecules, and Diseases, vol. 41, no. 2, pp. 158–165, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Ferrucci and L. Balducci, “Anemia of aging: the role of chronic inflammation and cancer,” Seminars in Hematology, vol. 45, no. 4, pp. 242–249, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Makipour, B. Kanapuru, and W. B. Ershler, “Unexplained anemia in the elderly,” Seminars in Hematology, vol. 45, no. 4, pp. 250–254, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Blick, S. A. Sherwin, M. Rosenblum, and J. Gutterman, “Phase I study of recombinant tumor necrosis factor in cancer patients,” Cancer Research, vol. 47, no. 11, pp. 2986–2989, 1987. View at Google Scholar · View at Scopus
  56. G. D. Roodman, A. Bird, D. Hutzler, and W. Montgomery, “Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells,” Experimental Hematology, vol. 15, no. 9, pp. 928–935, 1987. View at Google Scholar · View at Scopus
  57. W. Xiao, K. Koizumi, M. Nishio et al., “Tumor necrosis factor-α inhibits generation of glycophorin A+ cells by CD34+ cells,” Experimental Hematology, vol. 30, no. 11, pp. 1238–1247, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. H. A. Papadaki, H. D. Kritikos, V. Valatas, D. T. Boumpas, and G. D. Eliopoulos, “Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-α antibody therapy,” Blood, vol. 100, no. 2, pp. 474–482, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. F. Morceau, M. Dicato, and M. Diederich, “Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis,” Mediators of Inflammation, vol. 2009, Article ID 405016, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. W. Jelkmann, “Proinflammatory cytokines lowering erythropoietin production,” Journal of Interferon & Cytokine Research, vol. 18, no. 8, pp. 555–559, 1998. View at Google Scholar · View at Scopus
  61. R. T. Means Jr. and S. B. Krantz, “Inhibition of human erythroid colony-forming units by γ interferon can be corrected by recombinant human erythropoietin,” Blood, vol. 78, no. 10, pp. 2564–2567, 1991. View at Google Scholar · View at Scopus
  62. P. Minoo, M. M. Zadeh, R. Rottapel, J. J. Lebrun, and S. Ali, “A novel SHP-1/Grb2-dependent mechanism of negative regulation of cytokine-receptor signaling: contribution of SHP-1 C-terminal tyrosines in cytokine signaling,” Blood, vol. 103, no. 4, pp. 1398–1407, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. I. Neumcke, B. Schneider, J. Fandrey, and H. Pagel, “Effects of pro- and antioxidative compounds on renal production of erythropoietin,” Endocrinology, vol. 140, no. 2, pp. 641–645, 1999. View at Publisher · View at Google Scholar · View at Scopus
  64. F. Lang, K. S. Lang, P. A. Lang, S. M. Huber, and T. Wieder, “Mechanisms and significance of eryptosis,” Antioxidants & Redox Signaling, vol. 8, no. 7-8, pp. 1183–1192, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. R. D. Semba, K. V. Patel, L. Ferrucci et al., “Serum antioxidants and inflammation predict red cell distribution width in older women: the Women's Health and Aging Study I,” Clinical Nutrition, vol. 29, no. 5, pp. 600–604, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Takeda, T. Toda, S. Shinohara, Y. Mogi, and N. Matsui, “Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin,” American Journal of Kidney Diseases, vol. 40, no. 1, pp. 104–109, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. T. Gainsford, T. A. Willson, D. Metcalf et al., “Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 25, pp. 14564–14568, 1996. View at Publisher · View at Google Scholar · View at Scopus
  68. T. Ganz and E. Nemeth, “The hepcidin-ferooportin system as a therapeutic target in anemias and iron overload disorders,” Hematology, vol. 2011, pp. 538–542, 2011. View at Google Scholar
  69. E. Nemeth, M. S. Tuttle, J. Powelson et al., “Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization,” Science, vol. 306, no. 5704, pp. 2090–2093, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. J. L. Babitt, F. W. Huang, D. M. Wrighting et al., “Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression,” Nature Genetics, vol. 38, no. 5, pp. 531–539, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. X. Alvarez-Hernandez, J. Liceaga, I. C. McKay, and J. H. Brock, “Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor,” Laboratory Investigation, vol. 61, no. 3, pp. 319–322, 1989. View at Google Scholar · View at Scopus
  72. F. M. Torti and S. V. Torti, “Regulation of ferritin genes and protein,” Blood, vol. 99, no. 10, pp. 3505–3516, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. H. Tilg, H. Ulmer, A. Kaser, and G. Weiss, “Role of IL-10 for induction of anemia during inflammation,” Journal of Immunology, vol. 169, no. 4, pp. 2204–2209, 2002. View at Google Scholar · View at Scopus
  74. N. C. Andrews, “The iron transporter DMT1,” The International Journal of Biochemistry & Cell Biology, vol. 31, no. 10, pp. 991–994, 1999. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Soe-Lin, S. S. Apte, M. R. Mikhael, L. K. Kayembe, G. Nie, and P. Ponka, “Both Nramp1 and DMT1 are necessary for efficient macrophage iron recycling,” Experimental Hematology, vol. 38, no. 8, pp. 609–617, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. S. Ludwiczek, E. Aigner, I. Theurl, and G. Weiss, “Cytokine-mediated regulation of iron transport in human monocytic cells,” Blood, vol. 101, no. 10, pp. 4148–4154, 2003. View at Publisher · View at Google Scholar · View at Scopus
  77. D. M. Wrighting and N. C. Andrews, “Interleukin-6 induces hepcidin expression through STAT3,” Blood, vol. 108, no. 9, pp. 3204–3209, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. F. B. Sow, G. R. Alvarez, R. P. Gross et al., “Role of STAT1, NF-κB, and C/EBPβ in the macrophage transcriptional regulation of hepcidin by mycobacterial infection and IFN-γ,” Journal of Leukocyte Biology, vol. 86, no. 5, pp. 1247–1258, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. G. Nicolas, C. Chauvet, L. Viatte et al., “The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation,” The Journal of Clinical Investigation, vol. 110, no. 7, pp. 1037–1044, 2002. View at Publisher · View at Google Scholar · View at Scopus
  80. E. Nemeth, S. Rivera, V. Gabayan et al., “IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin,” The Journal of Clinical Investigation, vol. 113, no. 9, pp. 1271–1276, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. W. P. den Elzen and J. Gussekloo, “Anaemia in older persons,” The Netherlands Journal of Medicine, vol. 69, no. 6, pp. 260–267, 2011. View at Google Scholar
  82. X. Han, D. B. Zhou, C. M. Xu et al., “The effects and mechanisms of erythropoietin on hepcidin of human monocytes,” Zhonghua Xue Ye Xue Za Zhi, vol. 32, no. 7, pp. 468–472, 2011. View at Google Scholar
  83. D. R. Ashby, D. P. Gale, M. Busbridge et al., “Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin,” Haematologica, vol. 95, no. 3, pp. 505–508, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. W. B. Ershler, A. S. Artz, and M. M. Kandahari, “Recombinant erythropoietin treatment of anemia in older adults,” Journal of the American Geriatrics Society, vol. 49, no. 10, pp. 1396–1397, 2001. View at Publisher · View at Google Scholar · View at Scopus
  85. P. Agnihotri, M. Telfer, Z. Butt et al., “Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa,” Journal of the American Geriatrics Society, vol. 55, no. 10, pp. 1557–1565, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. K. Maiese, Z. Z. Chong, and Y. C. Shang, “Raves and risks for erythropoietin,” Cytokine & Growth Factor Reviews, vol. 19, no. 2, pp. 145–155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. A. K. Singh, L. Szczech, K. L. Tang et al., “Correction of anemia with epoetin alfa in chronic kidney disease,” The New England Journal of Medicine, vol. 355, no. 20, pp. 2085–2098, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. M. A. Pfeffer, E. A. Burdmann, C. Y. Chen et al., “A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease,” The New England Journal of Medicine, vol. 361, no. 21, pp. 2019–2032, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. K. Maiese, F. Li, and Z. Z. Chong, “New avenues of exploration for erythropoietin,” The Journal of the American Medical Association, vol. 293, no. 1, pp. 90–95, 2005. View at Publisher · View at Google Scholar · View at Scopus
  90. G. Lippi, M. Franchini, and E. J. Favaloro, “Thrombotic complications of erythropoiesis-stimulating agents,” Seminars in Thrombosis and Hemostasis, vol. 36, no. 5, pp. 537–549, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. S. A. Tjulandin, P. Bias, R. Elsässer, B. Gertz, E. Kohler, and A. Buchner, “Epoetin theta in anaemic cancer patients receiving platinum-based chemotherapy: a randomised controlled trial,” Archives of Drug Information, vol. 3, no. 3, pp. 45–53, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. M. Haag-Weber, K. U. Eckardt, W. H. Hörl, S. D. Roger, A. Vetter, and K. Roth, “Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study,” Clinical Nephrology, vol. 77, no. 1, pp. 8–17, 2012. View at Google Scholar
  93. L. Kerkhofs, G. Boschetti, A. Lugini, D. L. Stanculeanu, and A. G. Palomo, “Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience,” Future Oncology, vol. 8, no. 6, pp. 751–756, 2012. View at Google Scholar
  94. M. H. Bross, K. Soch, and T. Smith-Knuppel, “Anemia in older persons,” American Family Physician, vol. 82, no. 5, pp. 480–487, 2010. View at Google Scholar · View at Scopus
  95. D. Baribeault and M. Auerbach, “Iron replacement therapy in cancer-related anaemia,” American Journal of Health-System Pharmacy, vol. 68, no. 10, supplement 2, pp. S4–S14, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. National Comprehensive Cancer Network, NCCN clinical practice guidelines in oncology: cancer- and chemotherapy-induced anemia, version 1.2011, http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
  97. D. W. Coyne, T. Kapoian, W. Suki et al., “Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) study,” Journal of the American Society of Nephrology, vol. 18, no. 3, pp. 975–984, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. R. L. Jurado, “Iron, infections, and anemia of inflammation,” Clinical Infectious Diseases, vol. 25, no. 4, pp. 888–895, 1997. View at Google Scholar · View at Scopus
  99. A. Macciò, C. Madeddu, G. Gramignano, C. Mulas, E. Sanna, and G. Mantovani, “Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-β for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study,” The Oncologist, vol. 15, no. 8, pp. 894–902, 2010. View at Publisher · View at Google Scholar · View at Scopus
  100. M. Poli, D. Girelli, N. Campostrini et al., “Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo,” Blood, vol. 117, no. 3, pp. 997–1004, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. A. U. Steinbicker, C. Sachidanandan, A. J. Vonner et al., “Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation,” Blood, vol. 117, no. 18, pp. 4915–4923, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. E. Fung, J. Hsu, R. Damoiseaux, T. Ganz, and E. Nemeth, “Identification of hepcidin antagonists through a high throughput screening approach,” The FASEB Journal, vol. 24, supplement 1011.6, 2011. View at Google Scholar
  103. J. Coward, H. Kulbe, P. Chakravarty et al., “Interleukin-6 as a therapeutic target in human ovarian cancer,” Clinical Cancer Research, vol. 17, no. 18, pp. 6083–6096, 2011. View at Google Scholar
  104. M. V. Blagosklonny, “Aging: ROS or TOR,” Cell Cycle, vol. 7, no. 21, pp. 3344–3354, 2008. View at Google Scholar · View at Scopus
  105. V. N. Anisimov, M. A. Zabezhinski, I. G. Popovich et al., “Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice,” Cell Cycle, vol. 10, no. 24, pp. 4230–4236, 2011. View at Google Scholar
  106. S. Majumder, A. Caccamo, D. X. Medina et al., “Life-long rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1βand NMDA signaling,” Aging Cell, vol. 11, no. 2, pp. 326–335, 2012. View at Google Scholar
  107. M. M. Mihaylova and R. J. Shaw, “The AMPK signalling pathway coordinates cell growth, autophagy and metabolism,” Nature Cell Biology, vol. 13, no. 9, pp. 1016–1023, 2011. View at Google Scholar
  108. A. Salminen and K. Kaarniranta, “AMPactivated protein kinase (AMPK) controls the aging process via an integrated signaling network,” Ageing Research Review, vol. 11, pp. 230–241, 2012. View at Google Scholar
  109. S. Fogarty and D. G. Hardie, “Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer,” Biochimica et Biophysica Acta, vol. 1804, no. 3, pp. 581–591, 2010. View at Publisher · View at Google Scholar · View at Scopus
  110. M. C. Recio, I. Andújar, and J. L. Ríos, “Anti-inflammatory agents from plants: progress and potential,” Current Medicinal Chemistry, vol. 19, no. 14, pp. 2088–2103, 2012. View at Google Scholar
  111. M. P. Kähkönen, A. I. Hopia, H. J. Vuorela et al., “Antioxidant activity of plant extracts containing phenolic compounds,” Journal of Agricultural and Food Chemistry, vol. 47, no. 10, pp. 3954–3962, 1999. View at Publisher · View at Google Scholar · View at Scopus
  112. E. W. Qian, D. T. Ge, and S. K. Kong, “Salidroside promotes erythropoiesis and protects erythroblasts against oxidative stress by up-regulating glutathione peroxidase and thioredoxin,” Journal of Ethnopharmacology, vol. 133, no. 2, pp. 308–314, 2011. View at Publisher · View at Google Scholar · View at Scopus
  113. C. Selmi, P. S. C. Leung, L. Fischer et al., “The effects of Spirulina on anemia and immune function in senior citizens,” Cellular & Molecular Immunology, vol. 8, no. 3, pp. 248–254, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. S. P. Hsu, C. K. Chiang, S. Y. Yang, and C. T. Chien, “N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients,” Nephron—Clinical Practice, vol. 116, no. 3, pp. c207–c216, 2010. View at Publisher · View at Google Scholar · View at Scopus
  115. J. S. Jurenka, “Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research,” Alternative Medicine Review, vol. 14, no. 2, pp. 141–153, 2009. View at Google Scholar · View at Scopus
  116. E. K. Perry, A. T. Pickering, W. W. Wang, P. J. Houghton, and N. S. L. Perry, “Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy,” Journal of Pharmacy and Pharmacology, vol. 51, no. 5, pp. 527–534, 1999. View at Publisher · View at Google Scholar · View at Scopus
  117. O. I. Aruoma, Y. Hayashi, F. Marotta, P. Mantello, E. Rachmilewitz, and L. Montagnier, “Applications and bioefficacy of the functional food supplement fermented papaya preparation,” Toxicology, vol. 278, no. 1, pp. 6–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  118. M. J. R. Howes and E. Perry, “The role of phytochemicals in the treatment and prevention of dementia,” Drugs and Aging, vol. 28, no. 6, pp. 439–468, 2011. View at Publisher · View at Google Scholar · View at Scopus
  119. L. T. Goodnough, “Iron deficiency syndromes and iron-restricted erythropoiesis,” Transfusion, vol. 52, no. 7, pp. 1584–1592, 2012. View at Google Scholar
  120. N. Agarwal and J. T. Prchal, “Erythropoietic agents and the elderly,” Seminars in Hematology, vol. 45, no. 4, pp. 267–275, 2008. View at Publisher · View at Google Scholar · View at Scopus
  121. W. Xie and L. Du, “Diabetes is an inflammatory disease: evidence from traditional Chinese medicines,” Diabetes, Obesity and Metabolism, vol. 13, no. 4, pp. 289–301, 2011. View at Publisher · View at Google Scholar · View at Scopus